Biotech Sleeper MCET (MultiCell Technologies) Surging Higher as its Fa N2-4 immortalized Human Hepatocytes Cell Lines Patent Gains Traction
microcapdaily.com
MCET (MultiCell Technologies) has been heating up and running northbound in recent weeks running out of the triple zeroes and trading several hundred million shares a day with a recent high of $0.0016 per share. The stock has been under heavy accumulation recently and volume has picked up substantially as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards.
Investors should be cautious with MCET. The Company has not filed or issued a press release in years. MCET is pink no information on OTCMarkets (MCET is DARK on OTCMarkets) and has not put out a filing or a press release in years. MCET once owned a valuable patent portfolio however many of these patents were lost due to the Company not filing the mandatory maintenance fee at 4, 8 and at twelve years after the U. S. Patent office granted them patents. However, the Company may still own a number of patents including the Fa N2-4 immortalized Human Hepatocytes Cell Lines. Recently, David Lewis paid the Patent maintenance fee on the Fa N2-4 immortalized Human Hepatocytes Cell Lines. Back in 2009 MCET was granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. (Microcapdaily would like to make it clear this information is years old) There is a growing movement of shareholders led by Mcetdreamer who contend the Fa N2-4 immortalized Human Hepatocytes Cell Lines patent is currently being infringed upon by a number of Company’s and MCET management has done nothing about it; Barbara Newman wrote at one point she “didn’t know what they can do about it.”
 MCET (MultiCell Technologies) is a biopharmaceutical company developing therapeutic candidates based on modulation of the immune system plus new antiviral treatments to address influenza and other infectious diseases. (Microcapdaily would like to make it clear this information is years old) MultiCell produces cell lines used by pharmaceutical companies to screen and develop new drugs and therapeutics. The Company owns a majority interest in its two subsidiary companies MultiCell Immunotherapeutics, Inc. (MCTI) of which MultiCell holds 85.1% of the outstanding shares and Xenogenics of which MultiCell holds 95.3% of the outstanding shares. This information is out of date.
It is not exactly certain who is currently in charge of the Company; it could be the Company’s old CEO Jerry Newmin who is now close to 80 years old or his wife Barbara or the Company’s director, Ed Sigmond; a Partner at Sigmond & Johnson, Inc. Mr. Sigmond was also President at Kestrel Holdings, Inc., Chairman, CEO & Head-Investor Relations at The Great American Food Chain, Inc., Managing Partner & Owner at The Elbow Room, and a Director & Partner at Na Zdravi Ventures. He is/was on the Board of Directors at MultiCell Technologies, Inc.
Back when MultiCell was more active the Company described itself as: (this information is years old and much of its may no longer be valid) MultiCell is the vendor of two lines of immortalized human hepatocytes to the pharmaceutical and biotech industries. These progenitor cells and immortalized liver cells have been validated for use in drug discovery by XenoTech, Pfizer and Bristol Meyers Squibb. (Microcapdaily would like to make it clear this information is years old)
MultiCell’s immortalized human hepatocyte lines closely resemble primary human liver cells in morphology and function. (Microcapdaily would like to make it clear this information is years old) Hepatocytes express drug-metabolizing enzymes that biotransform drugs or substances ingested into the body, so they help predict the effect of a compound on human livers. MultiCell’s cell lines are sensitive to compounds that increase the expression of CYP3A4, an essential feature of in vitro model systems when studying drug-drug interactions. They eliminate the problem of limited supply and organ donor variability that restrict the use of harvested human liver cells for enzyme induction, cellular toxicity assays and other in vitro screening. The bio-reactivity of MultiCell’s cell lines may save years of time and millions of dollars during pre-clinical drug discovery, development and testing stages. Hepatocytes metabolize or de-toxify drugs or substances ingested into the body. Drug failures or FDA rejections due to hepatotoxicity and/or drug-drug interactions now cost the pharmaceutical industry an estimated $2 billion each year. It costs about $900 million to develop and test a new medicine.
MultiCell also has intellectual property in the area of drug discovery and stem cells and the patented Sybiol(TM) synthetic bio-liver therapeutic liver assist device. MultiCell holds two patents on novel strategies for isolation of adult human liver cells, and cell clusters or doublets, invented by Dr. Ronald A. Faris, Senior Vice President and Chief Scientific Officer of MutliCell and Director of Research with Rhode Island Hospital. Obtaining stem cells from adult tissues avoids the ethical issues and the contamination issues associated with embryonic or fetal stem cells. Liver stem cells may play a key role in transplantation for tissue regeneration and therapeutic use including the clinical management of metabolic liver disorders and heart disease as well as potential diagnostic applications. The use of liver stem cells to treat diseases, such as Hepatitis C, may greatly enhance quality of life and avoid costly whole organ liver transplantation. MultiCell believes its patented stem cell techniques are unique within the cell therapy market. (Microcapdaily would like to make it clear this information is years old)
The Company’s subsidiary XenoTech (Microcapdaily would like to make it clear this information is years old) was founded by Andrew Parkinson, Ph.D. to study drug metabolism and safety. XenoTech provides products and contract research services to pharmaceutical companies throughout the world to optimize discovery, development and approval of new drugs. XenoTech’s products and services, including MultiCell’s hepatocytes, are marketed in Japan by Nosan Corporation and by tebu-bio in Europe. (this information is years old and much of its may no longer be valid)
Investor sentiment is very high:
To Find out the inside Scoop on MCET Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
MCET once owned a valuable patent portfolio however many of these patents were lost due to the Company not filing the mandatory maintenance fee at 4, 8 and at twelve years after the U. S. Patent office granted them patents. However, the Company may still own a number of patents including the Fa N2-4 immortalized Human Hepatocytes Cell Lines. Recently, David Lewis paid the Patent maintenance fee on the Fa N2-4 immortalized Human Hepatocytes Cell Lines. (Microcapdaily would like to make it clear this information is years old)
Back in 2009 MCET was granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays.
MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies. MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.
There is a growing movement of shareholders led by Mcetdreamer who contend the Fa N2-4 immortalized Human Hepatocytes Cell Lines patent is currently being infringed upon by a number of Company’s and MCET management has done nothing about it; Barbara Newman wrote at one point she “didn’t know what they can do about it.”
The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma in humans arises by maturation arrest of liver stem cells. Jerry Newmin, Chairman & CEO of MultiCell Technologies commented at the time of this release in 2009: “MultiCell intends to use its human liver cell and liver stem cell assets to identify therapeutic targets and new drug candidates specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer. We believe our engineered human liver cell lines will play an important role as proxies for normal human liver cells in our effort to identify drug targets.” MCET is stop no information on otcmarkets. This information is out of date.
The National Cancer Institute (NCI) in 2008 stated there were approximately 21,400 new cases of hepatocellular carcinoma and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.
Microcapdialy has written about MCET before.Back in 2015 we wrote of MCET: “MultiCell Technologies, Inc. (OTCMKTS:MCET) made a big move up today off its $0.0002 lows on massive volume. The move is a huge welcome to shareholders who have endured months of nothing since the run this one made in March 2014. The big move today came after MCET announced a research & development and product license agreement with Oxis Biotech to create three novel antibody-drug conjugates (ADCs) containing OXIS’ lead drug candidates using MCIT’s proprietary ADC platform technology. MultiCell Technologies, Inc. (OTCMKTS:MCET) is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease and cancer. MCET majority owned subsidiary is MultiCell Immunotherapeutics, a biotechnology company developing novel therapeutics and drug delivery platform technologies to treat a variety of human diseases. MCIT’s next-generation antibody drug conjugates provide for the simultaneous targeted delivery of multiple drugs from a single antibody. This unique, targeted co-delivery capability enables the localization of both drugs within a target cell where they exert their biological effect and helps to minimize adverse off-target effects.” MCET drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.
For More on MCET Subscribe Right Now!
MCET has been heating up and running northbound in recent weeks running out of the triple zeroes and trading several hundred million shares a day with a recent high of $0.0016 per share. The stock has been under accumulation recently and volume has picked up substantially as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. Investors are cautious in MCET as the Company is pink no information on OTCMarkets and has not put out a filing or a press release in years. All information here is old and outdated. MCET once owned a valuable patent portfolio however many of these patents were lost due to the Company not filing the mandatory maintenance fee at 4, 8 and at twelve years after the U. S. Patent office granted them patents. However, the Company may still own a number of patents including the Fa N2-4 immortalized Human Hepatocytes Cell Lines. Recently, David Lewis paid the Patent maintenance fee on the Fa N2-4 immortalized Human Hepatocytes Cell Lines. (Microcapdaily would like to make it clear this information is years old) Back in 2009 MCET was granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. (Microcapdaily would like to make it clear this information is years old) The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. here is a growing movement of shareholders led by Mcetdreamer who contend the Fa N2-4 immortalized Human Hepatocytes Cell Lines patent is currently being infringed upon by a number of Company’s and MCET management has done nothing about it; Barbara Newman wrote at one point she “didn’t know what they can do about it.” MCET is stop no information on otcmarkets. We will be updating on MCET when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MCET. |
